Skip to Content

CHROMIUM (51CR) EDTA 3.7 MBQ/ML SOLUTION FOR INJECTION

Active substance(s): CHROMIUM EDETATE (51CR)

View full screen / Print PDF » Download PDF ⇩
Transcript
P587302-1177502-438682.qxd:P587301-1160769-18380

17/1/13

4. Possible side effects
Like all medicines, Chromium EDTA Injection can
cause side effects: for example fainting, although
not everybody gets them.
Allergic reactions
If you have an allergic reaction when you are in
hospital or a clinic having the scan, tell the doctor
or nurse straight away. The signs may include:
• skin rash or itching or flushing
• swelling of the face
• difficulty in breathing.
If any of the side effects above happen after you
leave the hospital or clinic go straight to the
casualty department of your nearest hospital.
If any of the side effects gets serious, or if you
notice any side effects not listed in this leaflet,
please tell your doctor or nurse.
5. How to store Chromium EDTA Injection
Chromium EDTA Injection is kept out of the reach
and sight of children.
The product label includes the correct storage
conditions and the expiry date for the batch.
Hospital staff will ensure that the product is
stored and disposed of correctly and not used
after the expiry date stated on the label.
6. Further information
What Chromium EDTA Injection contains
• The active ingredient is chromium-51 edetate.
Each ml of Chromium (51Cr) EDTA contains 3.7
MBq (Megabecquerel – the unit in which
radioactivity is measured) of chromium-51
edetate as an aqueous solution.
• The other ingredients are disodium EDTA,
benzyl alcohol and water for injections.

10:34

Page 1

What Chromium EDTA Injection looks like and
contents of the pack
Chromium EDTA Injection is supplied as a single
colourless glass vial containing a solution for
injection.
Marketing Authorisation Holder and
Manufacturer
GE Healthcare Limited
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA
United Kingdom
This leaflet was last approved in 09/2012.
Marketing Authorisations
UK: PL 00221/0108
Ireland: PA 240/20/1
GE and the GE Monogram are trademarks of
General Electric Company.

GE Healthcare

PATIENT
INFORMATION

Chromium (51Cr)
EDTA
3.7 MBq/ml solution for
Injection
Chromium-51 edetate
CJ13P

1 1 7 7 5 0 2

P/5873/02

P587302-1177502-438682.qxd:P587301-1160769-18380

17/1/13

PACKAGE LEAFLET: INFORMATION FOR THE USER
Chromium (51Cr) EDTA 3.7 MBq/ml solution for
injection
(called Chromium EDTA Injection in this leaflet)
Chromium-51 edetate
Read all of this leaflet carefully before you are
given Chromium EDTA Injection.
• Keep this leaflet. You may need to read it
again.
• If you have any further questions, ask your
doctor.
• If any of the side effects gets serious, or if you
notice any side effects not listed in this leaflet,
please tell your doctor or nurse.
In this leaflet:
1. What Chromium EDTA Injection is and what it is
used for
2. Before you are given Chromium EDTA injection
3. How Chromium EDTA Injection is given
4. Possible side effects
5. How to store Chromium EDTA Injection
6. Further information
1. What Chromium EDTA Injection is and what
it is used for
This medicine is for diagnostic use only. It is used
only to help identify illness.
Chromium EDTA Injection is a
‘radiopharmaceutical’ medicine. It is given before
a scan and helps a special camera see inside a
part of your body.
• It contains an active ingredient called
‘chromium edetate’.

10:34

Page 2

• Once injected it can be seen from outside your
body by a special camera used in the scan.
• The scan can help your doctor see how well
your kidneys are working.
2. Before you are given Chromium EDTA
Injection
You should not be given Chromium EDTA
Injection:
• If you are allergic (hypersensitive) to the active
ingredient or any other ingredient. (Listed in
Section 6).
Do not have Chromium EDTA Injection if the
above applies to you. If you are not sure talk to
your doctor or nurse.
Premature babies or newborn babies (neonates)
must not be given Chromium EDTA Injection. (See
“Important information about some of the
ingredients of Chromium EDTA Injection”).
Take special care with Chromium EDTA Injection
Check with your doctor or nurse before having
Chromium EDTA Injection:
• If you are pregnant or think you might be
pregnant.
• If you are on a low sodium diet.
Taking other medicines
Please tell your doctor or nurse if you are taking
or have recently taken any other medicines,
including medicines obtained without a
prescription. This includes herbal medicines. This
is because some medicines can affect the way
Chromium EDTA Injection works.
No medicines have been reported that affect the
way Chromium EDTA Injection works. But it is still
best to tell your doctor or nurse if you are taking
any other medicines.

Having Chromium EDTA Injection with food and
drink
• Your doctor may recommend that you drink
plenty of fluids and pass water (urinate) as
often as possible in the hours after the
injection.
Pregnancy and breast-feeding
You must tell your doctor if you are pregnant or
think you may be pregnant. Your doctor will only
use this product if it is considered that the benefit
outweighs the risk.
Do not breast-feed if you are given Chromium
EDTA Injection. This is because small amounts of
‘radioactivity’ may pass into the mother’s milk. If
you are breast-feeding, your doctor may wait
until you have finished breast-feeding before
using Chromium EDTA Injection. If it is not
possible to wait your doctor may ask you to:
• stop breast feeding for 4 hours, and
• use formula feed for your child, and
• express (remove) breast milk and throw away
the milk.
Your doctor will let you know when you can start
breast-feeding again.
Driving and using machines
Ask your doctor if you can drive or use machines
after you have been given Chromium EDTA
Injection.

Important information about Chromium EDTA
Injection
When Chromium EDTA Injection is used you are
exposed to radioactivity.
• Your doctor will always consider the possible
risks and benefits before you are given the
medicine.
Ask your doctor if you have any questions.
3. How Chromium EDTA Injection is given
Chromium EDTA Injection will be given to you by a
specially trained and qualified person.
• Chromium EDTA Injection will always be used in
a hospital or clinic.
• They will tell you anything you need to know for
its safe use.
Your doctor will decide on the dose that is best
for you.
The usual dose is:
• One single injection or a single injection
followed by a type of drip called a slow
infusion.
Samples that may be required after you have
had Chromium EDTA Injection
• Samples of your blood will be collected,
possibly for up to 24 hours, after the injection.
• Samples of your urine may be collected.

Important information about some of the
ingredients of Chromium EDTA Injection
• Chromium EDTA Injection contains benzyl
alcohol. Benzyl alcohol may cause toxic
reactions and allergic reactions in infants and
children up to 3 years old.
turn over ®

L587103-1177501-428185.qxd:-

17/1/13

12:52

Page 1

6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be
mixed with other medicinal products.
6.3 Shelf life
The shelf-life of the product is not more than 90 days after the date of
release.
The reference date of the product is 60 days before expiry.
6.4 Special precautions for storage
Store below 25°C. Do not freeze.
Store in accordance with national regulations for radioactive materials.
6.5 Nature and contents of container
The product is supplied in a 10 ml Type I Ph.Eur. clear, colourless, borosilicate
glass vial sealed with a PTFE faced rubber closure and oversealed with an
aluminium overseal with an aperture. Each vial is packed within a radiation
shielding container of lead metal.
Pack size: 37 MBq (10 ml vial)
6.6 Special precautions for disposal and other handling
Normal safety precautions for handling radioactive materials should be
observed. After use, all materials associated with the preparation and
administration of radiopharmaceuticals, including any unused product and
its container, should be decontaminated or treated as radioactive waste
and disposed of in accordance with the conditions specified by the local
competent authority. Contaminated material must be disposed of as
radioactive waste via an authorised route.
7 MARKETING AUTHORISATION HOLDER
GE Healthcare Limited
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA
United Kingdom
8 MARKETING AUTHORISATION NUMBERS
UK:
PL 00221/0108
Finland: 11192
Sweden: 80022
Australia: AUST R 17364
9
UK

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation
05 July 1999

Date of last renewal
28 May 2005

10 DATE OF REVISION OF THE TEXT
09/2012
11 DOSIMETRY
The table below shows the dosimetry as calculated according to the
Publication 80 of the ICRP (International Commission on Radiological
Protection, Radiation dose to Patients from Radiopharmaceuticals,
Pergamon Press 1998).

Organ
Adrenals
Bladder wall
Bone surfaces
Brain
Breast
Gall bladder
GI-tract
Stomach
SI
Colon
(ULI
(LLI

Absorbed dose
per unit activity administered (mGy/MBq)
Adult
15 year 10 year
5 year
1 year
7.2E-04 9.2E-04 1.4E-03 2.1E-03 3.9E-03
2.4E-02 3.1E-02 3.8E-02 3.6E-02 6.6E-02
8.2E-04 1.0E-03 1.4E-03 2.1E-03 3.8E-03
4.7E-04 6.0E-04 9.9E-04 1.6E-03 2.9E-03
4.3E-04 5.6E-04 8.3E-04 1.3E-03 2.5E-03
7.8E-04 1.0E-03 1.6E-03 2.2E-03 3.4E-03
6.9E-04
1.1E-03
1.3E-03
9.6E-04
1.7E-03

8.5E-04
1.4E-03
1.6E-03
1.2E-03
2.1E-03

1.3E-03
2.0E-03
2.2E-03
1.8E-03
2.8E-03

2.0E-03
2.7E-03
2.9E-03
2.6E-03
3.3E-03

3.5E-03
4.8E-03
4.9E-03
4.3E-03)
5.6E-03)

Heart
Kidneys
Liver
Lungs
Muscles
Oesophagus
Ovaries
Pancreas

6.3E-04
1.8E-03
6.5E-04
5.5E-04
7.7E-04
5.7E-04
1.6E-03
7.5E-04

8.2E-04
2.2E-03
8.4E-04
7.3E-04
9.6E-04
7.4E-04
2.0E-03
9.5E-04

1.3E-03
3.0E-03
1.3E-03
1.1E-03
1.4E-03
1.1E-03
2.7E-03
1.5E-03

1.9E-03
4.4E-03
2.0E-03
1.7E-03
1.9E-03
1.7E-03
3.3E-03
2.2E-03

3.4E-03
7.8E-03
3.6E-03
3.1E-03
3.6E-03
3.2E-03
5.8E-03
4.0E-03

Red marrow
Skin
Spleen
Testes
Thymus
Thyroid
Uterus

7.4E-04
4.7E-04
6.7E-04
1.2E-03
5.7E-04
5.6E-04
2.8E-03

9.3E-04
5.8E-04
8.7E-04
1.6E-03
7.4E-04
7.4E-04
3.4E-03

1.3E-03
8.9E-04
1.3E-03
2.5E-03
1.1E-03
1.2E-03
4.6E-03

1.8E-03
1.4E-03
2.0E-03
3.0E-03
1.7E-03
1.9E-03
5.1E-03

3.2E-03
2.6E-03
3.7E-03
5.4E-03
3.2E-03
3.5E-03
8.8E-03

Remaining organs

7.7E-04

9.7E-04

1.4E-03

2.0E-03

3.6E-03

Effective
dose (mSv/MBq)

2.0E-03

2.6E-03

3.4E-03

3.9E-03

7.1E-03

The data presented above assume a body retention half-time of 100
minutes and a renal transit time of 5 minutes. Data are also presented for
abnormal renal function in which the retention half-time is 1000 minutes
and the renal transit time is increased to 20 minutes.
The table below shows the dosimetry as calculated according to the
Publication 53 of the ICRP (International Commission on Radiological
Protection, Radiation dose to Patients from Radiopharmaceuticals,
Pergamon Press 1987).

Abnormal Renal Function
Organ
Adrenals
Bladder wall
Bone surfaces
Breast
GI-tract
Stomach wall
Small intest
ULI wall
LLI wall

Absorbed dose
per unit activity administered (mGy/MBq)
Adult
15 year 10 year
5 year
1 year
4.5E-03 5.0E-03 7.7E-03 1.2E-02 2.1E-02
2.1E-02 2.9E-02 4.2E-02 6.4E-02 1.2E-01
3.6E-03 4.2E-03 6.4E-03 9.8E-03 1.8E-02
3.2E-03 3.2E-03 4.8E-03 7.6E-03 1.4E-02
4.1E-03
4.5E-03
4.3E-03
4.6E-03

4.7E-03
5.5E-03
5.2E-03
5.7E-03

7.2E-03
8.4E-03
7.7E-03
8.8E-03

1.1E-02
1.3E-02
1.2E-02
1.3E-02

1.9E-02
2.3E-02
2.1E-02
2.3E-02

Kidneys
Liver
Lungs
Ovaries
Pancreas

8.3E-03
3.8E-03
3.3E-03
4.6E-03
4.3E-03

1.0E-02
4.6E-03
4.2E-03
6.0E-03
5.2E-03

1.4E-02
7.2E-03
6.3E-03
9.1E-03
8.1E-03

2.1E-02
1.1E-02
9.7E-03
1.4E-02
1.2E-02

3.6E-02
2.0E-02
1.8E-02
2.5E-02
2.2E-02

Red marrow
Spleen
Testes
Thyroid
Uterus

4.0E-03
4.0E-03
3.7E-03
3.1E-03
5.8E-03

4.8E-03
4.8E-03
4.6E-03
4.3E-03
7.1E-03

7.1E-03
7.3E-03
7.2E-03
6.8E-03
1.1E-02

1.0E-02
1.1E-02
1.1E-02
1.1E-02
1.7E-02

1.8E-02
2.0E-02
2.1E-02
2.0E-02
2.9E-02

Other tissue

3.4E-03

4.1E-03

6.3E-03

9.9E-03

1.8E-02

Effective dose
equivalent
(mSv/MBq)

5.2E-03

6.5E-03

9.7E-03

1.5E-02

2.7E-02

For this product, the effective dose equivalent to a 70 kg adult resulting
from an administered activity of 1.1 to 6 MBq is typically 0.0025 to
0.014 mSv in the case of normal kidney function and is 0.0057 to 0.031 mSv
under conditions of abnormal renal function.
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
They may be received, used and administered only by authorised persons in
designated clinical settings. Their receipt, storage, use, transfer and
disposal are subject to the regulations and/or appropriate licences of the
local competent official organisations (see section 6.6).
The administration of radiopharmaceuticals creates risks for other persons
from external radiation or contamination from spills of urine, vomiting, etc.
Radiation protection precautions in accordance with national regulations
must therefore be taken.
13 OTHER INFORMATION
Manufacturer
GE Healthcare Limited
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA
United Kingdom
GE and the GE Monogram are trademarks of General Electric Company.

GE Healthcare

HEALTHCARE PROFESSIONAL
INFORMATION

Chromium (51Cr)
EDTA
3.7 MBq/ml solution
for injection
Chromium-51 edetate
CJ13P

1 1 7 7 5 0 1

L/5871/03

L587103-1177501-428185.qxd:-

17/1/13

12:52

Page 2

PACKAGE LEAFLET: INFORMATION FOR HEALTHCARE PROFESSIONAL
1 NAME OF THE MEDICINAL PRODUCT
Chromium (51Cr) EDTA 3.7 MBq/ml solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Chromium-51 edetate 3.7 MBq/ml (37 MBq/vial) at the activity reference
date.
The formulation contains 0.64 mg/ml chromium edetate. Chromium-51 has
a physical half-life of approximately 28 days and decays by gamma
emission with a principal energy of 0.32 MeV.
This medicinal product contains:
• Sodium: 0.23 mg/ml. This needs to be taken into consideration for
patients on a controlled sodium diet.
• Benzyl Alcohol: 10 mg/ml
For a full list of the excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, violet solution.
4

CLINICAL PARTICULARS

4.1 Therapeutic indications
This medicinal product is for diagnostic use only.
Chromium-51 edetate is indicated for the determination of glomerular
filtration rate in the assessment of renal function.
4.2 Posology and method of administration
The normally recommended dose for adults and the elderly is 1.1-6.0 MBq
by intravenous injection or continuous infusion. The actual activity
administered will depend on the technique used to determine the renal
clearance and on that used for radioactivity detection. Higher activities up
to a maximum of 11 MBq may be appropriate for use in conjunction with
external counting techniques.
The activity to be administered to children may be calculated approximately
by correcting on a weight, body surface area or age basis the activity to
adults. For children under about one year of age, the target organ size in
relation to the whole body must also be taken into consideration. The
maximal activity to be used in children must not exceed 3.7 MBq. Chromium
(51Cr) EDTA contains benzyl alcohol. It must not be given to premature
babies or neonates.
The following methods of administration are recommended:
Single intravenous injection
Because of the complexities of the infusion technique (see below) a single
injection technique is normally used. This method obviates the need for
urine collection. However, it is not suitable for use with patients with oedema
since in such patients equilibration of the administered chromium-51 edetate
between the plasma and interstitial fluid may take up to 12 hours.

The single injection plasma clearance is calculated from the injected
amount of chromium-51 edetate and the decrease of activity in plasma
samples as a function of time. A number of different methods are available
for analysis of the plasma disappearance curve, one of which is presented
below.
A single intravenous administration of 3.7 MBq of chromium-51 edetate is
given. Venous samples are taken at appropriate intervals (for example, two,
three, and four hours after administration) with another at 24 hours if renal
failure is suspected. The venous samples are spun and the plasma
separated and counted, together with an aliquot of the given dose. The net
plasma activities are then expressed in terms of fractional dose and plotted
against time on a log-linear plot. A regression line is then fitted to the data
and the line extrapolated back to the ordinate axis. The turnover rate k is
determined from the slope of the line. The apparent distribution volume of
the tracer V is obtained by dividing the count rate due to the administered
dose by the plasma concentration given by the intercept on the ordinate
axis. The plasma clearance C is then given by:
C = kV
In order to correlate the chromium-51 edetate values with standard inulin
clearance values, a correction factor may be applied to the final result if this
is required.
Continuous intravenous infusion
A priming administration of 1.85 MBq is given intravenously followed by the
infusion of a solution containing 37 kBq/ml at a rate of 0.5 ml/minute. After
about 40 minutes, the plasma concentration becomes constant. A urine
collection lasting about 15 minutes is then started and a venous sample
taken at the mid-time. This process is repeated with rapid separation and
counting of the plasma radioactivity until constant plasma activity is
observed in two successive samples. The values of the urine and the plasma
concentrations and the urine flow are then substituted into the equation:
C = UV
P
(where C = vol. of plasma cleared per unit time, U = urine concentration,
V = urinary flow, P = plasma concentration)
to give the clearance. When the urinary flow is low, it may be necessary to
catheterise the bladder in order to remove the whole of the urine sample for
a particular time period.
Alternative methods for determining glomerular filtration rate (GFR) using
chromium-51 edetate may be used in certain centres.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Must not be given to premature babies or neonates.
4.4 Special warnings and precautions for use
This medicinal product contains benzyl alcohol. Benzyl alcohol may cause
toxic reactions and anaphylactoid reactions in infants and children up to 3
years old.
To reduce the radiation dose to the bladder and an accumulation of
radioactivity in it, the patient should be asked to drink additional fluids and
to void the bladder as often as possible in the hours following administration.
4.5 Interaction with other medicinal products and other forms of
interaction
No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation
No data are available on the use of this product in human pregnancy.
Animal reproduction studies have not been performed.
When it is necessary to administer radioactive medicinal products to
women of childbearing potential, information should always be sought
about pregnancy. Any woman who has missed a period should be assumed
to be pregnant until proven otherwise. Where uncertainty exists it is
important that radiation exposure should be the minimum consistent with
achieving the desired clinical information. Alternative techniques which do
not involve ionising radiation should be considered.
Radionuclide procedures carried out on pregnant women also involve
radiation doses to the foetus. Only imperative investigations should be
carried out during pregnancy, when the likely benefit exceeds the risk
incurred by the mother and the foetus.
Avoidance of pregnancy following administration of chromium-51 edetate
is not necessary for a woman of child-bearing potential because of the low
absorbed radiation dose associated with such an administration.
Before administering a radioactive medicinal product to a mother who is
breast feeding, consideration should be given as to whether the
investigation could be reasonably delayed until the mother has ceased
breast feeding and as to whether the most appropriate choice of
radiopharmaceutical has been made, bearing in mind the secretion of
activity in breast milk. If the administration of chromium-51 edetate is
considered necessary, breast feeding should be interrupted for 4 hours and
the expressed feeds discarded, after which time the level of activity in the
milk will not result in a radiation dose to the child greater than 1mSv.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been
performed.
4.8 Undesirable effects
The frequencies of undesirable effects are defined as follows:
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to
<1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known
(cannot be estimated from the available data)
Immune system disorders
Not known:
Hypersensitivity
Nervous system disorders
Not known:
Syncope vasovagal
Unwanted effects have been reported infrequently after single or repeated
intravenous administrations of chromium-51 edetate such that the
incidence of individual reactions cannot be quantified. Limited details are
available, but mild allergic phenomena have been described. The
causation of the adverse events reported to date has not been firmly
established.
For each patient, exposure to ionising radiation must be justifiable on the
basis of likely benefit. The activity administered must be such that the
resulting radiation dose is as low as reasonably achievable bearing in mind
the need to obtain the intended diagnostic or therapeutic result.
Exposure to ionising radiation is linked with cancer induction and a potential
for development of hereditary defects. For diagnostic nuclear medicine
investigations the current evidence suggests that these adverse effects will
occur with low frequency because of the low radiation doses incurred.
For most diagnostic investigations using a nuclear medicine procedure the
effective dose is less than 20mSv. Higher doses may be justified in some
clinical circumstances.

4.9 Overdose
In the event of an accidental administration of an overdose of chromium-51
edetate, the absorbed radiation dose to the patient should be reduced by
increasing the elimination of the radionuclide from the body. This may be
done by more frequent emptying of the urinary bladder by hydration,
diuretics and catheterisation.
5

PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: diagnostic radiopharmaceuticals, renal
system, chromium (51Cr) edetate, ATC code: V09CXO4
Chromium-51 edetate is a chemically stable, hydrophilic metal chelate. It is
metabolically inert. Renal function is unaffected even by large amounts of
chromium edetate. At the chemical concentrations and activities used
chromium-51 edetate does not appear to exert any pharmacodynamic effects.
5.2 Pharmacokinetic properties
Following intravenous administration, the chromium-51 edetate complex is
excreted almost exclusively by the kidneys via the glomerular membrane
(less than 1% faecal excretion in 24 hours reported for an anuric patient).
Less than 0.5% plasma protein binding occurs. In patients with normal or
near-normal glomerular filtration rate the recovery of unchanged chelate in
the urine during the first 24 hours after administration is close to 100% of
the injected activity, cumulative faecal clearance accounting for less than
0.1%. There is no significant tubular secretion or re-absorption of chromium-51
edetate. However, a small amount of tubular re-absorption, some whole
body retention or complex dissociation have each been postulated to
explain the known but small underestimation of inulin clearance by
chromium-51 edetate.
After intravenous administration, the chromium-51 edetate equilibrates
within the intra- and extravascular spaces, a process taking between 30
and 90 minutes. Beyond this period a constant percentage of the
chromium-51 edetate present in the extracellular fluid is excreted by the
kidneys per unit time. Total body retention is described by a double
exponential function.
The mean value of the glomerular filtration rate in the normal adult is
approximately 130 ml/min in men and 120 ml/min in women (normalised
for body surface area of 1.73 m2).
5.3 Preclinical safety data
It has been reported that no toxic effects were noted in dogs following
intravenous infusion for a period of 36 hours of 1.5 g chromium edetate/kg.
Intravenous administration of a formulation of chromium-51 edetate to rats
and mice has indicated that the average lethal dose is more than 1000
times the maximum recommended dose to humans. Repeat dose studies
with the same formulation revealed no detrimental clinical or histological
effects when the equivalent of more than 50 times the maximum
recommended human dose was administered to rats and dogs over a two
week period. Chromium-51 edetate is not intended for regular or
continuous administration.
Mutagenicity studies and long-term carcinogenicity studies have not been
carried out.
6

PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Disodium EDTA Ph.Eur.
Benzyl alcohol Ph.Eur.
Water for injections Ph.Eur.

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide